Caroline E. Rutten - Concepedia

Author

Caroline E. Rutten

Also Known As

Andreas E. Kremer, C E Rutten, C. E. Rutten, C.E. Rutten, Caroline E. Rutten, Caroline E Rutten, Caroline E. Rutten, Caroline Rutten

Publications

762

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center Amsterdam University Medical Centers Sanquin University of Amsterdam National Institute for Public Health and the Environment

About

Caroline E. Rutten is an author at Leiden University Medical Center specializing in immunology, medicine, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	470
2	Cell Biology	6	6	368
3	Health Sciences	1	1	62
4	Allergy	1	1	99
5	Blood Transplantation	1	1	13

Caroline E. Rutten

Publications

686

Citations

H-Index

Page 1

	Year	Citations
Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs, Liesbeth C. de Wreede, Journal of Clinical Investigation HistocompatibilityCell TherapyT Cell ReactivityT-regulatory CellImmunology	2017	99
High-Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning Cornelis A.M. van Bergen, Caroline E. Rutten, Edith D. van der Meijden, Cancer Research HistocompatibilityHlaImmunologyPathologyAntigen Processing	2010	85
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19 Sabine Haggenburg, Quincy Hofsink, Birgit I. Lissenberg‐Witte, JAMA Oncology	2022	81
Identification of phosphatidylinositol 4-kinase type II β as HLA class II-restricted target in graft versus leukemia reactivity Marieke Griffioen, Edith D. van der Meijden, Elisabeth H. Slager, Proceedings of the National Academy of Sciences HistocompatibilityCell TherapyHla ImmunogeneticsImmunologyPathology	2008	67
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients Sabine Haggenburg, Birgit I. Lissenberg‐Witte, Rob van Binnendijk, Blood Advances ImmunohematologyImmunodeficienciesHematology PatientsImmunologyImmunodominance	2022	62
HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia Caroline E. Rutten, Simone A.P. van Luxemburg-Heijs, Marieke Griffioen, Leukemia HlaHistocompatibilityHematological MalignancyHuman Leukocyte AntigenMalignant Blood Disorder	2008	54
Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or Absence of Graft-versus-Host Disease Caroline E. Rutten, Simone A.P. van Luxemburg-Heijs, Constantijn J.M. Halkes, Biology of Blood and Marrow Transplantation Cell TherapyImmunologySevere GvhdPathologyImmunotherapy	2012	50
A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome Raffaele Badolato, Laia Alsina, Antoine Azar, Blood	2024	39
HLA-DPB1 Mismatching Results in the Generation of a Full Repertoire of HLA-DPB1-Specific CD4+ T Cell Responses Showing Immunogenicity of all HLA-DPB1 Alleles Caroline E. Rutten, Simone A.P. van Luxemburg-Heijs, Edith D. van der Meijden, Biology of Blood and Marrow Transplantation	2010	30
Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia Sanja Stevanović, Marieke Griffioen, Bart Nijmeijer, Leukemia Radiation OncologyNod/scid MiceCell TherapyCancer ImmunosurveillanceImmunology	2011	28

Page 1